Steven Cohen’s Summit Therapeutics SMMT Stock Holding History

Steven Cohen’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,900	Closed	-$320K	–	4537
2026 Q1	$320K	Buy	+16,900	New	+$273K	﹤0.01%	3340

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's SMMT Position: Q2 2026 in Review

Steven Cohen increased its Summit Therapeutics (SMMT) stake by 372% in Q2 2026, buying an estimated $51.7M and bringing the position to 3,697,803 shares worth $53.9M. The position accounts for 0.06% of the portfolio, ranked #406.

Steven Cohen first reported a position in SMMT in Q1 2015 and has held it in 18 quarters since. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Steven Cohen held 3,697,803 shares of Summit Therapeutics worth $53.9M as of Q2 2026.
Steven Cohen bought 2,913,617 Summit Therapeutics shares in Q2 2026, an estimated $51.7M.
Summit Therapeutics made up 0.06% of Steven Cohen's portfolio in Q2 2026, its #406 holding.
Steven Cohen first reported a position in Summit Therapeutics in Q1 2015 and has held it in 18 quarters since.
241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.